Morgan Stanley Downgrades Valeant Pharmaceuticals (VRX) to Equalweight
Tweet
Share
E-mailGet Alerts VRX Hot Sheet
Price: $23.40 --0%
Rating Summary:
0 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 19 | Down: 16 | New: 47
Rating Summary:
0 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 19 | Down: 16 | New: 47
Join SI Premium – FREE
Morgan Stanley downgraded Valeant Pharmaceuticals (NYSE: VRX) from Overweight to Equalweight with a price target of $200.00 (from $284.00).
For an analyst ratings summary and ratings history on Valeant Pharmaceuticals click here. For more ratings news on Valeant Pharmaceuticals click here.
Shares of Valeant Pharmaceuticals closed at $179.60 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citi Downgrades Endeavor Group Holdings Inc (EDR) to Neutral
- Steel Authority of India Ltd (SAIL:IN) PT Raised to INR130 at JPMorgan
- Morgan Stanley Downgrades Logitech International (LOGI) to Underweight, 'Entering a New (Slower) Growth Paradigm'
Create E-mail Alert Related Categories
Analyst PT Change, Downgrades, Hot DowngradesRelated Entities
Morgan StanleySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
